Management of moderate to severe psoriasis with brodalumab-Real-world evidence from the LIBERO study

Psoriasis

Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)

Acta Derm Venereol

Lichtenberger R, Maul LV, Birkenmaier I, Oyanguren I, Ak M, Heidemeyer K, Schlapbach C, Yawalkar N, Egeberg A, Thomsen SF, Thyssen JP, Sorbe C, Boehncke WH, Conrad C, Cozzio A, Kokolakis G, Micheroli R, Wu JJ, Kündig T, Navarini A, Maul JT

doi: 10.2340/actadv.v105.42296

Rheumatoid Arthritis

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Arthritis Res Ther

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, McDearmon-Blondell E, Gao T, Lagunes-Galindo I, Strengholt S, Zisman D, Attar S

doi: 10.1186/s13075-025-03528-5

Psoriasis

Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Br J Dermatol

Alabas OA, Mason KJ, Yiu ZZN, Smith CH, Warren RB, Grifﬁths CEM, BADBIR study group

doi: 10.1093/bjd/ljaf017

PsoriasisPsoriatic ArthritisFurther Publications Rheumatology

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023

Adv Ther

Puig L, Sewerin P, Schuster C, Ng KJ, Papadimitropoulos M, Gadagamma S, Nuñez M, Lampropoulou A

doi: 10.1007/s12325-025-03258-9

Rheumatoid Arthritis

Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence

J Rheumatol

Freites Núñez D, Gallego A, García Dorta A, García-Valle A, Valero Expósito M, De la Morena Barrio I, Arconada C, Valero C, Fernández-Prada M, López I Gómez M, Álvarez de Cienfuegos A, López-Sánchez R, García Martos Á

doi: 10.3899/jrheum.2025-0102

Psoriatic Arthritis

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

Br J Dermatol

Graier T, Bordag N, Weger W, Laschober N, Ratzinger G, Jonak C, Prillinger K, Müllegger R, Mlynek A, Lange-Asschenfeldt B, Häring N, Hoetzenecker W, Posch C, Ellersdorfer C, Sator P, Gruber B, Hofer A, Gruber-Wackernagel A, Legat FJ, Großschädl K, Gruber V, Schadelbauer E, Repelnig M, Gressenberger P, Widnig A, Falkensteiner K, Salmhofer W, Wolf P

doi: 10.1093/bjd/ljaf394

Psoriasis

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

J Am Acad Dermatol

Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, Ucpinar S, Ma G, Hitraya E, Tilley MK, Papp KA, STRIDE investigators

doi: 10.1016/j.jaad.2025.07.013

Psoriasis

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

Adv Ther

Lebwohl MG, Koo JY, Jaworski J, Trefler J, Daniluk S, Dudek A, Baran W, Owczarek W, Kolinek J, Brzewski P, Sikora M, Krogulec M, Kim S, Bae Y, Jeon D, Choi E, Cha J, Lee H, Choi S, Pariser DM

doi: 10.1007/s12325-024-03100-8

Psoriasis

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study

Acta Derm Venereol

Sieborg J, Maul JT, Wu JJ, Loft NN, Skov L, Bryld LE, Rasmussen MK, Dam TN, Bertelsen T, Ajgeiy KK, Thomsen SF, Thyssen JP, Egeberg A, Thein D

doi: 10.2340/actadv.v105.42572

Related content

Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023

Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study